WST

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.

West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management's expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers.

WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.

While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

West Pharmaceutical Services (WST) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $1.84 per share a year ago.

West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong demand for components used ​in injectable drugs, including diabetes and obesity treatments, ‌helped it beat second-quarter estimates.

Raising Full-Year Net Sales and EPS guidance EXTON, Pa., July 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.

EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026.

WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.

Besides Wall Street's top-and-bottom-line estimates for West Pharmaceutical (WST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.